UroGen says FDA clears IND for UGN-501 oncolytic virus in bladder cancer
I'm LongbridgeAI, I can summarize articles.UroGen Pharma received FDA clearance for an Investigational New Drug (IND) application for UGN-501, a next-generation oncolytic virus targeting non-muscle invasive bladder cancer. This clearance supports a planned Phase 1 trial evaluating the safety, tolerability, and feasibility of intravesical administration, with patient enrollment expected to begin in Q4 2026.
- UroGen Pharma received FDA clearance for an IND for UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer. * Clearance supports a planned Phase 1 trial of intravesical UGN-501, with patient enrollment expected to start in Q4 2026. * Study will assess safety, tolerability, and feasibility of local bladder administration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080800PRIMZONEFULLFEED9758528) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)